Published in
Public Library of Science, PLoS ONE, 1(8), p. e53081, 2013
DOI: 10.1371/journal.pone.0053081
Links
- ORCID
- Public Library of Science
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib
,
Thomas Zander,
Lucia Nogova,
Carsten Kobe,
Deniz Kahraman,
Markus Dietlein,
Irini Papachristou,
Lukas Heukamp,
Reinhard Büttner,
Ron Boellaard,
Adriaan A. Lammertsma,
Silvia Querings,
Erich Stoelben,
Walburga Engel-Riedel,
Bernd Neumaier
and other authors.
Full text: Download
Abstract
3′-deoxy-3′-[18F]fluoro-L-thymidine (FLT) and 2′-deoxy-2′-[18F]fluoro-D-glucose (FDG) are used to visualize proliferative and metabolic activity of tumors. In this study we aimed at evaluating the prognostic value of FLT and FDG uptake measured by positron emission tomography (PET) in patients with metastatic non-small cell lung cancer (NSCLC) prior to systemic therapy with erlotinib. FLT and FDG maximum standardized uptake (SUVmax) values per patient were analyzed in 40 chemotherapy naive patients with advanced NSCLC (stage IV) before treatment with erlotinib. Prior therapy median SUVmax was 6.6 for FDG and 3.0 for FLT, respectively. In univariate analysis, patients with an FDG SUVmax